In case you missed it, this commercial for Cue COVID tests made its debut during the Super Bowl. Cue lab-quality COVID-19 tests are at-home, molecular tests that need no prescription or special ...

became the first company to receive De Novo authorization from the FDA for its Cue COVID-19 Molecular Test, designed for both home and point-of-care use. The de novo is a device classification ...

It then became the first molecular test to win EAU on March 5, 2021, from the Food and Drug Administration for at-home and over-the-counter use without a prescription.

Cue also received Emergency Use Authorization from the FDA for its molecular mpox test at the point-of-care.

Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.

The system performs rapid molecular analysis at the point-of-care and transmits test results to the Cue Health App on a connected mobile device.

Cue Health also developed a rapid, molecular Covid-19 test that it submitted to the FDA for emergency use authorization.

Cue’s accurate, fast, and reliable results make the easy-to-use test a convenient, cost-effective option for diagnosing patients at the office.

(RTTNews) - Cue Health (HLTH) has received Emergency Use Authorization from the FDA for its molecular test to detect the mpox virus. The nucleic acid amplification test is run on a Cue Reader, and ...